Regeneron: Study shows use of 2-antibody combo drug can help prevent serious illness, death
The findings showed the cocktail called Remdesivir reduced hospitalization or death by 70%. It also reduced the average hospital stay from 14 days to 10 days.
•
Mar 24, 2021, 2:21 AM
•
Updated 1,221 days ago
Share:
More Stories
Hometown Heroes in New York City
2ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
310ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
317ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
331ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
332ds agoHometown Heroes in New York City
2ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
310ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
317ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
331ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
332ds agoTarrytown-based Regeneron Pharmaceuticals released the results of its phase three trial of Remdesivir on Tuesday.
The findings showed the cocktail called Remdesivir reduced hospitalization or death by 70%. It also reduced the average hospital stay from 14 days to 10 days.
This is significant because this isn't a vaccine. It doesn't prevent the disease, it's for treating people after they're infected.
SEARCH FOR A CURE: Statistics and State Resources
Former President Donald Trump took the cocktail, which was still unproven, when he had COVID-19 in October.
Trump said Remdesivir did wonders for him.
The treatment is just as effective at half the dose, Regeneron also said.
